Clinical Trials
31 trialsNeratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Pembro+Chemo in Brain Mets
University of Kentucky
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Thomas Jefferson University
IntenSify
German Cancer Research Center
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
Albert Einstein College of Medicine
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Albert Einstein College of Medicine
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Albert Einstein College of Medicine
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
University of Washington
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Wake Forest University Health Sciences
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
UConn Health
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Case Comprehensive Cancer Center
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
University of Washington
NAC
University of Utah
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Case Comprehensive Cancer Center
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Vanderbilt-Ingram Cancer Center